Investigational Drug Information for Lapaquistat

What is the development status for investigational drug Lapaquistat?

Lapaquistat is an investigational drug.

There have been 16 clinical trials for Lapaquistat. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1^st 2005.

The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Hyperlipoproteinemias. The leading clinical trial sponsors are Takeda and [disabled in preview].

Summary for Lapaquistat

US Patents	0
International Patents	0
US Patent Applications	166
WIPO Patent Applications	73
Japanese Patent Applications	15
Clinical Trial Progress	Phase 3 (2005-09-01)
Vendors	31

Recent Clinical Trials for Lapaquistat

Title	Sponsor	Phase
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia	Takeda	Phase 3
Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia	Takeda	Phase 3
Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia	Takeda	Phase 2

See all Lapaquistat clinical trials

Clinical Trial Summary for Lapaquistat

Top disease conditions for Lapaquistat

Top clinical trial sponsors for Lapaquistat

See all Lapaquistat clinical trials

US Patents for Lapaquistat

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Lapaquistat Development Update, Patent Outlook, and Market Projection

Last updated: September 9, 2026

Lapaquistat, also known as TAK-475, is a discontinued Takeda cholesterol drug candidate that inhibited squalene synthase. Takeda halted clinical development in 2008 after liver-safety findings emerged in Phase III studies. Lapaquistat was never approved by the FDA, EMA, or other major regulators. Its current commercial market is therefore zero, with no credible generic, biosimilar, licensing, or relaunch opportunity visible from the public record.

What happened to lapaquistat development?

Lapaquistat was developed as an oral lipid-lowering therapy for patients with hypercholesterolemia. The compound inhibited squalene synthase, an enzyme involved in hepatic cholesterol synthesis upstream of cholesterol production targeted by statins.

Takeda evaluated lapaquistat as monotherapy and in combination with statins, including atorvastatin. The development strategy was designed to address patients who remained above lipid targets despite statin therapy.

Takeda discontinued the program after observing liver-related safety concerns in late-stage clinical development. The company announced in 2008 that it would stop further development of lapaquistat because of an unfavorable benefit-risk assessment related to liver enzyme elevations and hepatotoxicity concerns (Takeda Pharmaceutical Company, 2008).

Lapaquistat development timeline

Period	Development event
Early 2000s	Takeda advances lapaquistat, also known as TAK-475, as a cholesterol-lowering candidate
Mid-2000s	Phase II and Phase III studies evaluate monotherapy and statin-combination regimens
2007-2008	Late-stage studies identify liver-safety concerns
May 2008	Takeda announces termination of lapaquistat development
After 2008	No regulatory filing, approval, commercial launch, or resumed clinical program is reported
Current status	Discontinued clinical candidate with no marketed product

Clinical trial records show that lapaquistat reached advanced clinical testing but did not progress to a regulatory application or commercial launch (ClinicalTrials.gov, n.d.).

Why was lapaquistat discontinued?

The principal development failure was hepatic safety.

Lapaquistat’s mechanism affected cholesterol biosynthesis in the liver. Although the compound was intended to provide additional LDL-cholesterol reduction, clinical development generated liver enzyme abnormalities that limited its safety profile. Takeda concluded that the observed efficacy did not justify continued exposure to the safety risk.

The discontinuation was not caused by a failure to demonstrate any lipid-lowering activity. The commercial problem was that the magnitude and consistency of benefit were insufficient relative to available therapies, while the safety profile introduced a material regulatory barrier.

Lapaquistat also faced a difficult competitive environment:

• Generic statins were inexpensive and widely prescribed.
• Ezetimibe offered an established non-statin LDL-lowering option.
• High-intensity atorvastatin and rosuvastatin were increasingly effective at standard doses.
• PCSK9 inhibitors later established a more powerful but higher-cost pathway for difficult-to-treat patients.
• Combination products and guideline-driven treatment algorithms reduced the commercial space for a new oral mechanism with liver-safety concerns.

Is lapaquistat FDA approved?

No. Lapaquistat has no FDA approval and no U.S. prescription product.

The compound does not have an FDA-approved label, National Drug Code listing, or commercial dosage form. It also does not have FDA-recognized new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or approval-based regulatory exclusivity.

What is the Orange Book status of lapaquistat?

Lapaquistat has no active Orange Book listing because no lapaquistat product was approved by the FDA.

The FDA Orange Book lists patents and regulatory exclusivities associated with approved drug products. Since Takeda did not obtain approval for lapaquistat, there is no approved reference listed drug against which an ANDA applicant could file a conventional Paragraph IV challenge (U.S. Food and Drug Administration, n.d.-a).

Regulatory item	Lapaquistat status
FDA approval	None
Approved brand	None
Reference listed drug	None
Orange Book patent listing	None
FDA market exclusivity	None
ANDA pathway	Not commercially relevant without an approved reference product
Paragraph IV litigation	No established Orange Book-based litigation pathway
Authorized generic	None

When did lapaquistat lose exclusivity?

Lapaquistat did not lose marketed exclusivity because it never reached approval.

Any patent exclusivity associated with lapaquistat would have depended on individual patent claims, filing dates, terminal disclaimers, patent-term adjustment, patent-term extension, and jurisdiction. Those rights are separate from FDA market exclusivity. The public commercial record does not show an approved lapaquistat product or a live branded market that could be protected from generic entry.

The practical exclusivity timeline is therefore:

Exclusivity category	Status
Patent protection	Historical development-related patent filings may exist
FDA NCE exclusivity	Never granted
Orphan exclusivity	Not applicable
Pediatric exclusivity	Not applicable
Approved-product patent listing	None
Commercial exclusivity	None
Current enforceable product monopoly	None identified

A discontinued candidate can retain unexpired patents covering a compound, process, formulation, or use. Those rights do not create a commercial market without regulatory approval and clinical viability.

What patents protect lapaquistat?

Lapaquistat-related patent activity was associated with Takeda and its predecessor organizations, but patent ownership and enforceability must be assessed claim by claim and jurisdiction by jurisdiction.

The relevant patent categories would include:

1. Composition-of-matter claims covering the lapaquistat molecule or related squalene synthase inhibitors.
2. Pharmaceutical-composition claims covering tablets, salts, excipients, or dosage forms.
3. Method-of-treatment claims covering cholesterol reduction or treatment of hyperlipidemia.
4. Combination claims covering lapaquistat with statins or other lipid-lowering agents.
5. Manufacturing claims covering synthesis, intermediates, polymorphs, or purification.

No reliable commercial conclusion can be drawn from the existence of historical patent filings alone. Patent expiration does not restore a discontinued program, and an unapproved compound cannot generate ordinary generic substitution.

How strong is the lapaquistat patent estate?

The estate has low commercial strength despite the possibility that individual patents may have remained technically enforceable after development stopped.

Its practical weaknesses are:

• No approved product to support an Orange Book listing.
• No reference listed drug for ordinary ANDA substitution.
• No revenue stream to defend.
• No evidence of a current clinical-development sponsor.
• No demonstrated path to overcome the liver-safety issue.
• No established licensing market for the molecule.
• No current demand from generic manufacturers.

A historical composition patent can have legal value in research, licensing, or blocking positions. It does not create meaningful asset value if the compound cannot be developed safely.

Are there Paragraph IV challenges to lapaquistat?

No material Paragraph IV challenge is associated with lapaquistat.

Paragraph IV litigation generally arises when an ANDA applicant certifies that a listed patent for an approved reference drug is invalid, unenforceable, or not infringed. Lapaquistat has no FDA-approved reference product and no active Orange Book listing.

A company could theoretically seek approval through another regulatory route if clinical development resumed, but that would not be a conventional generic launch based on an existing lapaquistat reference product.

Are biosimilars or generic versions of lapaquistat possible?

Biosimilar risk is not applicable because lapaquistat is a small-molecule drug, not a biologic.

A generic version is theoretically possible only if a sponsor develops a viable regulatory package and addresses the absence of an approved reference product. In practical terms, a lapaquistat generic is not a realistic market scenario because:

• The original drug was never approved.
• No reference listed drug exists.
• The underlying safety issue remains unresolved.
• The compound would need renewed clinical development.
• Statins and newer lipid therapies provide stronger commercial alternatives.
• Physicians and payers would have little reason to adopt a discontinued candidate.

The likely development requirement would resemble a new drug program rather than a routine ANDA launch.

What formulations were protected by lapaquistat patents?

Lapaquistat was studied as an oral product, principally in tablet-based development programs. Public clinical records do not establish a commercially approved formulation.

Potential historical formulation protection may have covered:

• Immediate-release oral tablets.
• Solid pharmaceutical compositions.
• Specific dosage ranges.
• Salt or crystalline forms.
• Combination administration with statins.
• Formulations designed to improve stability or exposure.

No commercial formulation reached the market. Consequently, formulation patents do not create current substitution barriers comparable to those associated with an approved branded drug.

What is the current market projection for lapaquistat?

The current market projection is zero.

There are no reported lapaquistat sales, no approved product, no active commercial supply chain, and no established development partner. A near-term relaunch is unlikely because the central obstacle is clinical safety rather than patent expiry or manufacturing scale.

Lapaquistat market outlook

Market metric	Projection
Current sales	$0
Approved indications	0
Commercial products	0
Generic sales opportunity	Negligible
Biosimilar opportunity	Not applicable
Near-term launch probability	Very low
Licensing demand	Limited
Manufacturing demand	None identified
Revenue contribution to Takeda	$0

Any future value would depend on a sponsor proving that the liver-safety profile can be materially improved through a new formulation, dose strategy, patient-selection method, or combination regimen. The public record does not show such a program.

How does lapaquistat compare with competing cholesterol drugs?

Lapaquistat is commercially disadvantaged against both established and newer lipid-lowering therapies.

Therapy	Mechanism	Regulatory status	Commercial position
Lapaquistat	Squalene synthase inhibition	Discontinued; never approved	No market
Atorvastatin	HMG-CoA reductase inhibition	Approved; generic	Large established market
Rosuvastatin	HMG-CoA reductase inhibition	Approved; generic	High-potency generic therapy
Ezetimibe	NPC1L1 inhibition	Approved; generic and branded history	Established add-on therapy
Evolocumab	PCSK9 inhibition	Approved biologic	High-value specialty therapy
Alirocumab	PCSK9 inhibition	Approved biologic	Specialty lipid market
Bempedoic acid	ATP citrate lyase inhibition	Approved	Oral non-statin option
Inclisiran	PCSK9 RNA interference	Approved in some jurisdictions	Long-interval injectable therapy

Lapaquistat’s potential differentiator was a non-statin oral mechanism. That differentiation was not sufficient to offset hepatic risk and the availability of low-cost, effective alternatives.

What manufacturing and intellectual-property barriers remain?

Manufacturing is unlikely to be the principal barrier. A small-molecule oral compound could generally be manufactured using conventional pharmaceutical processes if the active pharmaceutical ingredient, impurity profile, solid-state form, and process controls were established.

The more significant barriers are:

• Re-establishing a scalable, current-good-manufacturing-practice process.
• Confirming freedom to operate around historical Takeda patents.
• Repeating toxicology and clinical studies.
• Demonstrating a clinically acceptable liver-safety margin.
• Identifying a population with an unmet treatment need.
• Securing a regulatory pathway for a previously discontinued molecule.
• Competing against inexpensive generic statins and established non-statin therapies.

Historical patents covering synthesis or intermediates could create process-development constraints, but those constraints would be secondary to clinical and regulatory risk.

What licensing deals involve lapaquistat?

No active licensing deal, co-development agreement, or commercial partnership for lapaquistat is publicly established after Takeda discontinued the program.

Takeda appears to have retained control of the development program through termination. There is no reported acquisition of lapaquistat by a specialty pharmaceutical company, no rights sale to a generic manufacturer, and no announced revival by an academic or biotechnology sponsor.

What litigation affects lapaquistat?

No significant active patent or product-liability litigation is publicly associated with lapaquistat’s current commercial position.

Because the compound was never approved and never marketed, it did not generate the litigation profile seen with commercial drugs. There is no known Orange Book patent dispute, ANDA litigation campaign, biosimilar litigation, or launch-at-risk settlement involving lapaquistat.

What generic launch scenarios exist for lapaquistat?

The realistic launch scenarios are limited.

Scenario 1: No development activity

This is the base case. Lapaquistat remains discontinued, with no revenue and no generic launch.

Scenario 2: Academic or biotech revival

A sponsor could revive the molecule if new data supported a safer dose or a narrowly defined patient population. This would require substantial nonclinical and clinical investment and would not resemble a routine generic program.

Scenario 3: Reformulation-based redevelopment

A sponsor could test a formulation intended to reduce hepatic exposure. The commercial value would remain uncertain because safety concerns may relate to mechanism or systemic exposure rather than formulation alone.

Scenario 4: Combination therapy

Lapaquistat could theoretically be studied with a statin or another lipid-lowering agent. This would need to demonstrate incremental LDL reduction without worsening liver risk. Existing combination options make this route commercially difficult.

Key Takeaways

• Lapaquistat, or TAK-475, is a discontinued Takeda cholesterol drug candidate.
• Takeda halted development in 2008 because of liver-safety concerns.
• The compound was never approved by the FDA or commercialized.
• Lapaquistat has no Orange Book listing, approved reference drug, or FDA exclusivity.
• Paragraph IV litigation and biosimilar competition are not applicable in the ordinary commercial sense.
• Historical patents may exist, but they do not support a current marketed monopoly.
• Current lapaquistat revenue is zero.
• The probability of near-term generic launch or commercial relaunch is very low.
• Any future value would depend on resolving the hepatic safety problem through new clinical evidence.

FAQs About Lapaquistat

Is lapaquistat still in clinical trials?

No active mainstream clinical-development program is publicly established. Takeda discontinued development after late-stage safety concerns in 2008.

What company developed lapaquistat?

Takeda Pharmaceutical Company developed lapaquistat, also known as TAK-475.

Was lapaquistat intended to replace statins?

No. It was developed as a distinct oral lipid-lowering mechanism and was evaluated both alone and with statins. Its potential commercial use included patients needing additional LDL reduction.

Can a pharmaceutical company buy lapaquistat rights?

A transaction would be legally possible if relevant rights remain available, but no active licensing or acquisition deal is publicly reported. The main barrier would be clinical safety, not ownership alone.

Does lapaquistat have a future in cardiovascular medicine?

Its future is limited unless new evidence demonstrates a clinically meaningful benefit with an acceptable hepatic safety profile. No such redevelopment program is publicly established.

References

1. ClinicalTrials.gov. (n.d.). Studies involving lapaquistat and TAK-475. U.S. National Library of Medicine. https://clinicaltrials.gov/

2. Takeda Pharmaceutical Company. (2008). Takeda discontinues development of TAK-475. Takeda Pharmaceutical Company Limited.

3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. National Library of Medicine. (n.d.). Lapaquistat. PubChem. https://pubchem.ncbi.nlm.nih.gov/